Cargando…

Health resource utilization associated with skeletal-related events: results from a retrospective European study

BACKGROUND: Bone complications, also known as skeletal-related events (SREs), are common in patients with bone metastases secondary to advanced cancers. OBJECTIVE: To provide a detailed estimate of the health resource utilization (HRU) burden associated with SREs across eight European countries. MET...

Descripción completa

Detalles Bibliográficos
Autores principales:	Body, Jean-Jacques, Pereira, João, Sleeboom, Harm, Maniadakis, Nikos, Terpos, Evangelos, Acklin, Yves Pascal, Finek, Jindrich, Gunther, Oliver, Hechmati, Guy, Mossman, Tony, Costa, Luis, Rogowski, Wojciech, Nahi, Hareth, von Moos, Roger
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2015
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4899504/ https://www.ncbi.nlm.nih.gov/pubmed/26253584 http://dx.doi.org/10.1007/s10198-015-0716-7

Ejemplares similares

Pathologic fracture and healthcare resource utilisation: A retrospective study in eight European countries
por: Body, Jean-Jacques, et al.
Publicado: (2016)

Healthcare-resource utilization associated with radiation to bone across eight European countries: Results from a retrospective study
por: von Moos, Roger, et al.
Publicado: (2018)

A real-world study assessing the use of bone-targeted agents and their impact on bone metastases in patients with prostate cancer treated in clinical practice in Europe
por: Body, Jean-Jacques, et al.
Publicado: (2018)

Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in real-world practice in six European countries
por: von Moos, Roger, et al.
Publicado: (2017)

Physicians’ preferences for bone metastases treatments in France, Germany and the United Kingdom
por: Qian, Yi, et al.
Publicado: (2018)

Patients’ preferences for bone metastases treatments in France, Germany and the United Kingdom
por: Hechmati, Guy, et al.
Publicado: (2014)

Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completion
por: Body, Jean-Jacques, et al.
Publicado: (2018)

An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three European countries
por: Body, Jean-Jacques, et al.
Publicado: (2017)

Outcome of COVID‐19 in multiple myeloma patients in relation to treatment
por: Susek, Katharina Helene, et al.
Publicado: (2020)

Comprehensive overview: efficacy, tolerability, and cost-effectiveness of irbesartan
por: Gialama, Fotini, et al.
Publicado: (2013)

Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases
por: von Moos, Roger, et al.
Publicado: (2015)

Incidental Use of Beta-Blockers Is Associated with Outcome of Metastatic Colorectal Cancer Patients Treated with Bevacizumab-Based Therapy: A Single-Institution Retrospective Analysis of 514 Patients
por: Fiala, Ondrej, et al.
Publicado: (2019)

Comparative evaluation of involved free light chain and monoclonal spike as markers for progression from monoclonal gammopathy of undetermined significance to multiple myeloma
por: Gran, Charlotte, et al.
Publicado: (2020)

Self-reported prevalence of atherothrombosis in a general population sample of adults in Greece; A telephone survey
por: Maniadakis, Nikos, et al.
Publicado: (2011)

Skin toxicity and quality of life during treatment with panitumumab for RAS wild-type metastatic colorectal carcinoma: results from three randomised clinical trials
por: Koukakis, Reija, et al.
Publicado: (2016)

Health resource utilization associated with skeletal-related events in patients with advanced breast cancer: results from a prospective, multinational observational study
por: Lüftner, Diana, et al.
Publicado: (2014)

Health Resource Utilization Associated with Skeletal-Related Events in Patients with Advanced Prostate Cancer: A European Subgroup Analysis from an Observational, Multinational Study
por: Bahl, Amit, et al.
Publicado: (2014)

An Assessment of Novel Biomarkers in Bone Metastatic Disease Using Multiplex Measurement and Multivariate Analysis
por: Windrichova, Jindra, et al.
Publicado: (2018)

Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients
por: Fiala, Ondrej, et al.
Publicado: (2020)

Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity
por: Major, Pierre P, et al.
Publicado: (2009)

Pharmacoeconomic considerations in the treatment of breast cancer
por: Pallis, Athanasios, et al.
Publicado: (2010)

The disease burden of chronic obstructive pulmonary disease in Greece
por: Kourlaba, Georgia, et al.
Publicado: (2016)

Economic evaluation of rivaroxaban in stroke prevention for patients with atrial fibrillation in Greece
por: Kourlaba, Georgia, et al.
Publicado: (2014)

An Evaluation of Diagnosis-Related Group (DRG) Implementation Focused on Cancer DRGs in Greek Public Hospitals
por: Panagiotopoulos, Panos, et al.
Publicado: (2019)

Conditioning with melphalan 200 mg/m(2) and subsequent ASCT improves progression‐free and overall survival in elderly myeloma patients compared to standard of care
por: Afram, Gabriel, et al.
Publicado: (2022)

Elective implant removal in symptomatic patients after internal fixation of proximal humerus fractures improves clinical outcome
por: Acklin, Yves P., et al.
Publicado: (2016)

BONE DISEASE
por: Terpos, Evangelos
Publicado: (2022)

Vaccination Against SARS-CoV-2 for Myeloma Patients: Do We Need a Booster Dose and How Frequent?
por: Terpos, Evangelos
Publicado: (2022)

Estimating the number of colorectal cancer patients treated with anti-tumour therapy in 2015: the analysis of the Czech National Cancer Registry
por: Pavlík, Tomáš, et al.
Publicado: (2012)

Regulatory brokerage: Competitive advantage and regulation in the field of regenerative medicine
por: Sleeboom-Faulkner, Margaret
Publicado: (2019)

Health state utilities for skeletal-related events secondary to bone metastases
por: Matza, Louis S., et al.
Publicado: (2013)

The Use of Novel Drugs Can Effectively Improve Response, Delay Relapse and Enhance Overall Survival in Multiple Myeloma Patients with Renal Impairment
por: Uttervall, Katarina, et al.
Publicado: (2014)

Deletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma
por: Duru, Adil Doganay, et al.
Publicado: (2015)

Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma
por: Nahi, Hareth, et al.
Publicado: (2019)

Dynamic follow‐up of smoldering multiple myeloma identifies a subset of patients at high risk of progression
por: Gran, Charlotte, et al.
Publicado: (2020)

Loading and Skeletal Development and Maintenance
por: Bergmann, P., et al.
Publicado: (2010)

Cancer epidemiology in Central and South Eastern European countries
por: Vrdoljak, Eduard, et al.
Publicado: (2011)

Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece
por: Tzanetakos, Charalampos, et al.
Publicado: (2014)

Economic evaluation of agomelatine relative to other antidepressants for treatment of major depressive disorders in Greece
por: Maniadakis, Nikos, et al.
Publicado: (2013)

Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features—An exploratory analysis of placebo-controlled trials
por: Coleman, Robert E., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_tl22hi4l6qek5gr7n2a3i1qqp6